GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Excelsior Biopharma Inc (ROCO:6496) » Definitions » Debt-to-Asset

Excelsior Biopharma (ROCO:6496) Debt-to-Asset : 0.28 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Excelsior Biopharma Debt-to-Asset?

Excelsior Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$82.9 Mil. Excelsior Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$355.6 Mil. Excelsior Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$1,578.3 Mil. Excelsior Biopharma's debt to asset for the quarter that ended in Dec. 2024 was 0.28.


Excelsior Biopharma Debt-to-Asset Historical Data

The historical data trend for Excelsior Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Excelsior Biopharma Debt-to-Asset Chart

Excelsior Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.22 0.22 0.24 0.28

Excelsior Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.27 0.28 0.28 0.28

Competitive Comparison of Excelsior Biopharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Excelsior Biopharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Excelsior Biopharma's Debt-to-Asset falls into.


;
;

Excelsior Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Excelsior Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(82.911 + 355.575) / 1578.343
=0.28

Excelsior Biopharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(82.911 + 355.575) / 1578.343
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Excelsior Biopharma  (ROCO:6496) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Excelsior Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Excelsior Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Excelsior Biopharma Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao E. Road, 5Floor, No.508, Sector 7, Nangang District, Taipei, TWN, 11561
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.

Excelsior Biopharma Headlines

No Headlines